Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jackie Napier

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
British Journal of Community Nursing|October 12, 2019
CorrespondenceJackie Napier, Laura Daly, Caroline E Gibson, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 3, 2016
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UKPhilip Hykin, Usha Chakravarthy, Andrew Lotery, et al.
Eye (London, England)|October 18, 2019
Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedemaIan Pearce, Clare Bailey, Emily Fletcher, et al.
Eye (London, England)|July 10, 2021
Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|March 21, 2023
Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|January 18, 2023
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 30, 2017
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 updatePraveen J Patel, Helen Devonport, Sobha Sivaprasad, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Eye (London, England)|January 16, 2026
Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panelRichard Gale, Mahmoud Husseiny Awad, Clare Bailey, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
British Journal of Community Nursing|October 12, 2019
CorrespondenceJackie Napier, Laura Daly, Caroline E Gibson, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 3, 2016
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UKPhilip Hykin, Usha Chakravarthy, Andrew Lotery, et al.
Eye (London, England)|October 18, 2019
Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedemaIan Pearce, Clare Bailey, Emily Fletcher, et al.
Eye (London, England)|July 10, 2021
Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|March 21, 2023
Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Eye (London, England)|January 18, 2023
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomesSobha Sivaprasad, Faruque Ghanchi, Simon P Kelly, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 30, 2017
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 updatePraveen J Patel, Helen Devonport, Sobha Sivaprasad, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 8, 2024
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of AfliberceptNirodhini Narendran, Clare Bailey, Louise Downey, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Eye (London, England)|January 16, 2026
Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panelRichard Gale, Mahmoud Husseiny Awad, Clare Bailey, et al.
Pageof 1